Promopharm, the Maghreb-based pharmaceutical promotion company, recorded revenues of 192.4 million Moroccan dirhams (MAD) in the third quarter of 2024. This marks a 5% increase compared to the same period last year, reflecting strong market performance and the success of its newly launched products.
In its quarterly financial report, the company highlighted that its product lineup and recent launches were key drivers of this growth. However, the firm also reported a significant rise in debt, up by 52% compared to 2023. This increase is attributed to ongoing investments aimed at expanding its production capabilities.
Since late 2020, Promopharm has embarked on a series of investment projects spanning 2021 to 2024. These initiatives are part of the company’s strategy to enhance its operational capacity and better meet growing market demands.
Promopharm’s continued focus on innovation and expansion underscores its ambition to remain a leading player in the regional pharmaceutical industry.
